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ABSTRAK 
Pemasangan kateter vena pusat(KVP) adalah teknik yang selalu digunakan untuk 
memberikan rawatan hemodialisis kepada pesakit-pesakit yang mengalami kegagalan buah 
pinggang. Walau bagaimanapun kepenggunaannya juga membawa beberapa masalah yang serius 
seperti jangkitan bakteria dan kematian. KVP juga membawa ~siko jangkitan Staphylococcus. 
Mupirocin adalah antibiotik yang terhasil secara semulajadi yang aktifterhadapjangkitan 
Staphylococcus termasuk rintang meticilin (MRSA) serta strain yang menghasilkan beta laktam. 
Satu kajian prospektiftelah dijalankan terhadap 28 orang pesakit hemodialisis untuk 
1nenganalisa peranan mupirocin sebagai pencegah jangkitan kateter vena pusat. Tigabelas pesakit 
telah menerima desinfeksi povidon iodine pada pangkal KVP (kumpulan kawalan) dan 15 pesakit 
menerima rawatan yang sama diikuti dengan penggunaan salap mupirocin 2% sejurus selepas 
kateter dimasukkan dan pada akhir setiap rawatan dialisis. Kesemua pesakit diawasi sehingga 
kateter dikeluarkan dan pemantauan dilakukan untuk mengetahui perkembangan jangkitan 
berkaitan dengan kateter. 
Kadar jangkitan didapati adalah ketara lebih rendah pada kumpulan mupirocin (6.7% 
berbanding 38.4 %, p < 0.05 ). Bakteremia Staphylococcus aureus dan1v1RSA telah diperhatikan 
berlaku pada 4 pesakit kumpulan kawalan ( 30.7%) dan ianya melibatkan 3 kematian berkaitan 
denganjangkitan. Ini tidak berlaku pada kumpulan mupirocin. Nisbah bahaya untuk mendapat 
jangkitan berkaitan dengan kateter adalah 7.7 kali lebih kepada pesakit yang tidak menerima 
mupirocin. 
Kesimpulannya penggunaan salap mupirocin pada bahagian pangkal kateter dapat 
mengurangkan risiko jangkitan berhubung dengan kateter terutamanya septisimia Staphylococcus 
aureus pada pesakit hemodialisis. 
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ABSTRACT 
Central venous catheterization (CVC) is a common technique to establish rapid and 
temporary access for the delivery of haemodialysis in patients with renal failure. However its 
usage also carry tremendous problems such as infection, sepsis and even death. CVC is a 
known risk factor fc;>r Staphylococcus infection and bacteraemia. Mupirocin is a naturally 
occurring antibiotic which is active against Staphylococcus aureus including methicillin 
resistant and beta lactamase producing strains. 
A randomized prospective trial was conducted to assess the role of mupirocin ointment · 
as a prophylaxis in catheter related infection in 28 haemodialysis patients. Of these 13 
received skin disinfecti~n at eve insertion site with povidone iodine (control group) and 15 
received the same treatment followed by topical application of 2% mupirocin ointment at the 
cannula site immediately following catheter placement and at the end of each dialysis session. 
Patients were followed up until catheter removal and were monitored for the development of 
catheter related infectiol) ( CRI). 
The proportion of CRI in mupirocin group was significantly lower than control ( 6. 7% 
vs. 38.4%, P < 0.05). Staphylococcus aureus and l\1RSA bacteraemia was observed in 4 
patients ( 30.7%) in control group and 3 ofthem died related to sepsis. None of these was 
observed in the mupirocin group. The hazard ratio of developing catheter related infection was 
7. 7 times greater in patients not receiving mupirocin. 
As a conclusion, topical mupirocin application at the catheter exit site significantly 
reduced the risk of catheter related infection especially Staphylococcus aureus septicaemia in 
haemodialysis patients. 
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ABSTRACT 
Central venous catheterization (CVC) is a common technique to establish rapid and 
temporary access for the delivery ofhaemodialysis.in patients with renal failure. However its 
usage also carry tremendous problems such ~ infection, sepsi~ and even death, . CVC is a 
~ • • ' • • - • • • • f 
known risk factor for Staphylococcus. infection and b~c~~ra~mia. :J.\4upirocin~isa n~turally 
. . ._ . . ,: . . . . . 
occurring antibiotic which is .active against Staphyloco~cus ~.ureus. including methicillin 
resistant and beta lactamase producing strains. 
A randomized prospective trial was conducted to assess the role of mupirocin ointment 
as a prophylaxis in catheter related infection in 28 haemodialysis patients. Of these 13 
received skin disinfection at eve insertion site with povidone iodine (control group) and 15 
received the same treatment followed by topical application of 2% mupiroc~ ointment at the 
• 0 
cannula site immediately following catheter placement and at the erid ·of each dialysis session. 
Patients were followed up until catheter removal and were monitored for the development of 
catheter related infection (CRI). 
The proportion ofCRI in mupirocin group was significantly lower than control (6.7% 
patients ( 30.7%) in control group and 3 of them died related to sepsis. None of these was 
observed in the mupirocin group. The hazard ratio of developing catheter related infection was 
7. 7 times greater in patients not receiving mupirocin. 
As a conclusion, topical mupirocin application at the catheter exit site significantly 
reduced the risk of catheter related infection especially Staphylococcus aureus septicaemia in 
haemodialysis patients. 
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INTRODUCTION 
Since their introduction in 1980's Central Venous Catheters (CVC) for haemodialysis 
have come to play an important role in the delivery of dialysis especially in acute renal failure 
patients or in end stage renal failure patients while awaiting definitive .renal replacement 
therapy. 
Unfortunately CVC is a double edge sword Tremendous advantages that it brings also 
carry tremendous problems and cost. Among the serious complications ·include catheter related 
infection that accounts for a large percentage of nosocomial infection. The emergence of 
catheter related infection is directly related to the duration of catheterization and the type of 
catheter used. The longer the catheter is in place, the higher the chances will be for the 
catheter to be infected and patients with silicon catheter were found to have increased 
incidence of catheter related infection ( 1 ). 
There are numerous data with regards to catheter related infection. · In a series of 102 
catheters studied by Capdevilla in 1993,40% developed catheter related infection and out of 
this one third of the catheter had to be removed, another third .were removed later after failing 
antibiotic therapy and only less than a third can be salvaged successfully(2). From Taiwan 
University Hospital experience, K. Y. Hung et al found that in 135 patients with a total of 168 
catheter placement, a total of21.4% of catheter related infection rate was observed(3). 
In another survey of infection associated with central venous catheter by Gosbel m et 
all995, in Sydney Australia, it was found that in 479 central venous catheter surveyed in 311 
3 
patients from April to August 1991, 11% had developed local infection while 6.7% developed 
systemic infection. Local infection was predictive of systemic infection but its absence did not 
exclude systemic infection and haemodialysis catheters were responsible for higher systemic 
infection rate than other catheter types( 4 ). 
Patients with chronic or end stage renal failure are also in a state of depressed immune 
function. Thus infectious complications leading to a high incidence of morbidity and mortality 
are well documented problems. There is a.number of partly interdependent factors responsible 
for the diminished Polymorphonuclear leukocytes (PMNL) functions (chemotaxis, 
phagocytosis, intracellular killing by proteolytic enzymes and toxic oxygen radicals) found in 
uraemia: iron overload, elevated levels of intracellular calcium and haemodialysis treatment 
per se has been shown to involved in altered PMNL functions. There is also increased clinical 
evidence for profound defects in the specific immune defense in uraemia, such as the high 
susceptibility to viral infections in uraemic patients, the deficient responses of their T 
lymphocytes, and the significantly depressed specific antibody responses (5). 
Renal failure patients are already immunocompromised and the insertion of central 
venous catheter for haemodialysis adds further risk to bacterial infection. The main approach 
to catheter relat~d infection .is prevention, and the current trend in the prevention of catheter 
related infection is based on the pathogenesis and pathophysiology of the infection. 
CRI begins with the simple colonization of a segment of the catheter by bacteria or 
fungi. These microorganisms grow and multiply, favoured by local factors that interfere with 
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the patient's immunologic defences for example fibrin sheath adhering to the catheter walls 
and the structure and make up of the catheter itself. Because the device is in intimate contact 
\vith the systemic circulation, it is understandable that catheter infection is often associated 
with bacteraemia, particularly when the catheter is in use ( 6). 
Microorganisms colonize the catheter by various routes. Migration from the catheter 
skin interface over the external surface or from the hub over the internal surface of the device 
to the catheter tip are the most common. Other pathways include haematogenous seeding from 
a distant focus of bacteraemia (7 ,8). Approximately about 50% of catheter related infections 
originate from the skin, 40% from the contaminated hub and 10% from other routes .(9, 1 0). 
From microbiology of catheter related infectionlbacteraemia there is a predominance of 
skin microorganism such as Staph. epidermidis, Staph. aureus, Bacillus species and 
Corynbacterium species. This also include the microorganism that contaminate the hands of 
medical personnel which is responsible for most of the hospital acquired infection such as 
Pseudomonas aeruginosa, Acinetobacter species, Stenotrophomanas mathophilia, Candida 
survey of infection associated with central venous catheter,it was found that Staphylococci 
were the predominant isolates and 40% of the methicillin- resistant Staphylococcus aureus 
bacteraemias detected were due to catheter related infection( 5). 
Several preventive strategies have been suggested and studied to reduce CRI which 
included (i) infusion therapy team, (ii) subcutaneous tunneling ofCVC, (iii) periodic flushing 
5 
of the catheter with an antibiotic solution (intraluminal antibiotic lock), (iv) antimicrobial 
coating of catheter on the external surface, (v) catheters with new antiseptic hub models and 
(vi) the use of ionic silver impregnated subcutaneous collagen cuff. 
In this study, we applied cutaneous antimicrobial at the catheter exit site with the 
intention to reduce or lower the microbial burden since this is the most common site of the 
infection. The topical antibiotic of concern is mupirocin. Mupirocin is a topical broad 
spectrum antibiotics which is active against staphylococcus aureus, including methicillin-
resistant stains, other staphylococci and streptococci. It is also active against gram-negative .. 
pathogens such as Escherichia coli and Haemophilus infeluenzae. 
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METHODOLOGY 
1. A prospective randomised controlled study. 
2. Patients with acute on chronic renal failure (eRF) or .end stage renal failure (ESRF) 
requiring haemodialysis using eve as a temporary venous access who satisfied the 
inclusion criteria and gave written consent were included. 
Inclusion criteria : 
(i) adult patients (age~ 13) 
(ii) eve for haemodialysis inserted into subclavian or internal jugular veins. 
Exclusion criteria : 
(i) pre-existing fever from any focus of infection at study entry 
(ii) patients with acute renal failure 
(iii) eve over femoral vein 
3. Double lumen eve (Gamcath-Gambro) were inserted by medical officers under 
aseptic Seldinger technique. 
4. Patients were recruited from 4 haemodialysis units in Northeast Malaysia. 
5. Patients were randomised into 2 groups. The first group (control) used 10% povidine 
the same treatment followed by application of 2% calcium mupirocin ointment. 
6. This was carried out after catheter placement and at the end of each dialysis session. 
7. Patients in both groups were followed up regularly until their catheters were removed. 
Inspection of the catheter site was done and body temperature was taken during each 
dialysis session {3 times each week). 
8. All patients had superficial swabs (skin & catheter surface) taken once every week. 
7 
9. CRI was classified into 2 categories. 
i. Exit Site Infection: infection localised to the catheter exit site characterized by 
localized redness; crusting & exudates and apositive superficial culture 
ii. Catheter Related Bacteraemia: systemic symptoms (fever,· rigors) and positive 
blood culture. 
I 0. In patients who developed symptoms and signs suggesting catheter related infection, 
superficial swabs together with blood cultures were taken from the catheter as well as 
from peripheral vein. 
11. During catheter removal in all patients, superficial swabs and catheter tip were again 
sent for culture. 
12. The endpoints of the study were:-
J.Microbial colonization (skin, catheter) 
2. Catheter related infection 
13. The duration of the study was 15 months (between 1st. July 1999 to 30th. September 
2000). 
14. Statistical analysis was done using SPSS version 9 programme. Student's 't' test was 
proportions. 
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RESULTS 
A total of 28 patients were recruited in the study over a -15 month period ( from 1st July 1999 
to 30th September 2000 ). Fifteen patients ~ere as~igned to prophylaxis with mupirocin and 13 
to the control group. The baseline characteris#cs of ~he p~tients in the study are shown in 
Table 1 
Tablet. Baseline· patient characteristics 
Characteristic Mupirocin ( n = 15) Control (n = 13) 
Age, years ( mean ) 48.13 48.92 
Male/Female,n(%) sn(s3.3/46.7) 7/6(53.8/46.2) 
Race,n(%) 
Malay 13(86.6) 11(84.6) 
Chinese 2(13.4) 1(7.7) 
Indian 
Others 1(7.7) 
Doagnosis,n (%) 
; 
Acute on CRF 2(13.4) 2(15.4) 
ESRF ' 13(86.6) 11(84.6) 
c~~a .. ~ii·~~~ ~v~r·~~~~~~-li:O.,i'i 
Hypertension 9 ·9 
Diabetes Mellitus 4 2 
lschaem ic heart 1 1 
disease 
Gout 1 ~ 1 
With regards to the site of catheter insertion, internal jugular vein 
catheterization (25 pataents) was preferred to subclavian vein (3 patients), as 
depicted in Figure 1 
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Figure 1. SUe of catheter insertion 
Dlntemal 
Jugular Vein 
fii Subclavian 
Vein 
The spectrum of micro-organisms isolated in both treatment groups are illustrated in Figure 2 
and tabulated according to colonization or CRI in Table 2. The proportion of p~tients wit4 CRI 
in the mupirocin group was much lower than control (6.7% [1 of 15] versus 38.4% [5 of 13], 
p = 0.045) 
Figure 2. Microorganism isolated 
DNo growth 
D Staph. Au reus 
0 Staph. Epidermidis 
t; Pseudomonas 
sp. 
lii Klebsiella sp. 
D B.subtilis 
* MRSA = Methicillin resistant Staph. au reus 
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Table 2. Micro-organism causing colonization a~«:l .. CRI 
•. ' · 
Microorganism Type of dressing 
Isolated 
·Mupirocin (n=15) Control(n=13) 
Colonization CRI Colonization CRI 
Staph. aureus 2(15.4o/~} 
MRSA 2(15.4) 
Staph. epidermidis 1(6.7%) 1(7.6%) 
Pseudomonas sp. 1(7.6%) 
Klebsiella so. 1 (6.7%) 
Bacillus subtilis 1 (6.7%) 
No growth 12 (80.0%) 7(53.8%) 
The microbiological outcome for patients in both groups with regards to 
bacterial colonization, exit site infection and catheter related bacteraemia 
are shown in Figure 2 . 
No. of 
patients 
Figure 2. Microbiological outcome 
4 _..,,..,..,.,=~,_. 
3.5 
3 
2.5 
2 
1.5 
1 
0.5 
0 -¥J-li:1:.:..~=~.L=.L::.!...!IIi 
Mupirocin Control 
Treat ment group 
12 
D Colonization 
IJJ Exit' site infection 
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The reasons for catheter removal in both groups are listed in Table 3. Catheter related infection 
necessitated catheter removal in all the patients in both treatment groups. The mean duration of 
catheter placement was longer in the mupirocin group compared to control but it was not 
statistically significant ( 49.00 days versus 25.15 days, P = 0. 053 ). There were 3 deaths in the 
control group, all related to CRI but there was no death in the mupirocin group. 
Table 3. Reasons for catheter remQval 
Reasons for catheter Mupirocin Cootrol ( P. Iodine) 
removal (n = 15) (n = 13) 
Catheter Related Infection 1(6.7°/o). 5(38.4o/o) 
Available permanent 11 (73.3o/o) 2(26.0o/o) 
access 
Renal function recoverr 2(26.0o/o) 
Catheter blockage 3(20.0o/o) 2(26.0o/o) 
Catheter slipped out 2(26.0o/o) 
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DISCUSSION 
In this study cutaneous mupirocin application to the catheter exit site effectively 
alleviated and reduced the microbial burden especially Staphylococcus aureus and methicillin 
resistant Staphylococcus aureus which are the main microorganism that cause serious catheter 
related infection and its complications. 
Mupirocin is a naturally occuring an~biotic and is produced by fermentation of the 
organism Pseudomonas fluorescens·. Mupirocin inhibits bacterial protein· synthesis by 
reversibly and specifically binding bacterial isoleucyl transter- RNAsynthetase. Due to this 
mode of action, mupirocin shows no cross resistance with chloramphenicol, erythromycin, 
fucidic acid, gent~ycin, lincomycin, methicillin, neomycin, novobiocin, penicillin, 
streptomycin and tetracycline. 
Mupirocin is not absorbed into systemic circulation and hence active at epidermal layer. 
The bacteria that are susceptible to the action of mupirocin are Staphylococcus aureus 
including methicilin resistant and beta lactamase producing strains, Staphylococcus 
epidermidis, Staphylococcus saprophyticus and Streptococcus pyog~nes. 
The outcome of patients with central venous catheter for haemodialysis as shown in 
figure 3 was observed, there was significant reduction in the number of catheter related 
infection in mupirocin group (6.7% versus 38.4%, P = 0.045). However, in terms of mean 
duration of catheter placement between the 2 study groups, although patients in the mupirocin 
group had longer mean duration of catheter placement, ranging from 6 to 154 days, there was 
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only marginal significance observed (49.00 days versus 25~15, P= 0.053). This could probably 
be due to the small number of patients who entered the study. 
Comparing the microorganisms isolated between the 2 groups, there was significant 
difference observed. There were only 20% of patients in the mupirocin group who had 
positive culture compared to 56% patients in the control group, P = 0.012. In the control 
group, of those who were culture positive, more than 70% had CRI and out of this, 80% is due 
to Staphylococcus aureus and methicillin resistant Staphylococcus aureus. None of these were 
observed in mupirocin group. 
Previous randomised control trials of mupirocin showed a five to seven fold decrease in 
the risk of colonization in central venous catheter inserted in jugular vein (15,16). However, 
this was offset by a higher risk of fungal colonization and infection especially candida species . 
because application of the ointment could interfere with the nonnal flora of the skin thus 
favoring fungal growth.. Fortunately none of our patients had fungal isolated especially in the 
mupirocin group. 
Regarding the reasons for catheter removal, referring to table 3, catheter related 
infection necessitated catheter removal in all the patients in both treatment group (38.4% in the 
control group vs 6. 7% in the povidone group). This carries important implications in terms of 
the total cost of hospitalization and prolonged antibiotic therapy as well as the extra cost of a 
new CVC to be inserted later since the CVC is the lifeline for the patients.More than 70% of 
patients in the mupirocin group had achieved renal replacement therapy either haemodialysis 
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via A V fistula or through continuous ambulatory peritoneal dialysis compared to only 26% of 
patients in the control group, P < 0. 05. This observation reflected better outcome in mupirocin 
treated group. This finding could be explained by significant reduction in the rate of catheter 
related infection so the patients had longer duration of catheter placement and more time can 
be utilized or spent for optimum work up before entering renal replacement programs. 
Several preventive strategies against catheter related infection have been studied and 
practiced including subcutaneous tunelling, intraluminal antibiotic locks and antiseptic hubs. 
These methods requires technical expertise and good financial status to maintain their use. The 
more economical and simple measure as in this study was by applying cutaneous antimicrobial 
at the catheter exit site with the intention to reduce or lower the microbial burden since this is 
the commonest site of entry of microorganism. 
Although it has not gained much attention in the prevention of CRI, mupirocin is a 
very useful drug due to its unique pharmacokinetics and most importantly it does not show 
cross resistance with most antibiotics. We also found that mupirocin is safe to be used since 
there were no adverse events observed during the trial phase. 
This study has shown that topical application of mupirocin ointment at the catheter exit 
site effectively reduced catheter-related infection in chronic renal failure patients on 
haemodialysis using eve. Mupirocin is also safe and easy to be used as well as more 
economical when compared to most of other preventive methods against CRI. 
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